Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts (NASDAQ:FDMT)
peterschreiber.media Goldman Sachs has reinstated its buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT), citing upcoming catalysts. The investment bank said…
peterschreiber.media Goldman Sachs has reinstated its buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT), citing upcoming catalysts. The investment bank said…